NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis

Xeris Biopharma Holdings, Inc. (XERS) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

XERS

$8.53

−$0.06 (−0.70%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare XERS with… →

XERS Key Statistics

As of Sep 4, 2026
Trading
Open
$8.50
Previous Close
$8.59
Day's Range
8.38–8.59
52-Week Range
5.25–10.08
Volume
1.03M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.85
Valuation
Market Cap
$1.56B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
21.87
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.64
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.10
Financials (FY)
Revenue (FY)
$291.85M+43.72%
Net Income (FY)
$554.00K
Profit marginThe share of revenue left as profit after all costs and taxes.
−5.12%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
182.32M
1-Year Return
+8.11%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
1.86M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

XERS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+8.66%
2025+131.56%
2024+44.26%
2023+76.69%
2022−54.61%
2021−40.45%
2020−30.21%
2019−58.53%
2018 (partial year)−15.92%

As of September 4, 2026.

XERS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$291.85M$554.00K0.2%
2024$203.07M−$54.84M−27.0%
2023$163.91M−$62.26M−38.0%
2022$110.25M−$94.66M−85.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$291.85M$249.28M$24.90M$554.00K0.2%
2024$203.07M$166.24M−$33.65M−$54.84M−27.0%
2023$163.91M$135.27M−$44.01M−$62.26M−38.0%
2022$110.25M$87.61M−$81.94M−$94.66M−85.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

XERS Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricXERSDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio4.642.30102% above
Profit margin−5.12%−3.14%2.0 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Xeris Biopharma Holdings, Inc. (XERS) is capitalised at $1.56B on the latest close. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. Headcount on file is 435.

The most recent close on file for XERS is $8.53, dated September 4, 2026. That is −$0.06 (−0.70%) against the previous close. Over the past 52 weeks the price has ranged from $5.25 to $10.08. The latest close sits 62.48% above that 52-week low.

Financial Health

In fiscal 2025, Xeris Biopharma Holdings, Inc. reported revenue of $291.85M. Against the prior fiscal year total of $203.07M, that is a change of +43.72%. Net income for the same year was $554.00K. The reported profit margin is −5.12%. That is 2 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to −0.1.

Across the 4 fiscal years on file, revenue moves from $110.25M in 2022 to $291.85M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 21.87. The price-to-sales ratio is 4.64. On price-to-sales that is 101.92% above the Drug Manufacturers - Specialty & Generic median of 2.3. The medians here are taken across 103 Drug Manufacturers - Specialty & Generic companies that report the metric.

The reported beta is 0.85. Annualized volatility over the trailing 8 years is 78.54%. Over the trailing twelve months the price has returned +8.11%. Measured over 5 years, that is +25.68% a year compounded.

Growth & Income

The record shows no dividend for XERS.

2026 is still running; the price is +8.66% year to date. Across the complete calendar years on file, 2025 returned +131.56% and 2019 returned −58.53%. Of the 7 complete calendar years on file, 3 finished higher.

Peer Comparison

Xeris Biopharma Holdings, Inc. (XERS) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Xeris Biopharma Holdings, Inc. XERS $1.56B —
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Xeris Biopharma Holdings, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Visit website →